Stem cell therapy for stroke recovery that goes beyond what rehabilitation alone can achieve.

The clinical evidence shows meaningful neurological improvement in stroke patients treated with stem cell therapy, particularly those in the chronic recovery phase. Across multiple systematic reviews and meta-analyses, MSC-based therapy has been associated with improvements in motor function, speech and language, cognitive clarity, and overall disability scores — in patients who had already reached the limits of conventional rehabilitation.

It is important to be clear about what effectiveness means in this context. Stem cell therapy does not reverse all damage caused by a stroke. What the research consistently shows is that it supports the brain's own repair mechanisms at the cellular level — reducing inflammation, promoting new blood vessel formation, and supporting myelin repair — in ways that rehabilitation alone cannot. The result for many patients is continued functional recovery that would not have occurred otherwise.

Results vary between individuals and depend on factors including the type of stroke, the regions of the brain affected, the time elapsed since the stroke, and the patient's current functional status. Improvement is gradual and develops over months following treatment, not days or weeks. You can review the specific studies supporting these outcomes in the research section above.

Currently, there are no FDA-approved stem cell treatments for stroke. The FDA's regulatory framework has not approved any stem cell therapy specifically for stroke recovery, which means that patients in the United States and Canada have very limited access to this treatment — and what is available is often restricted in cell source, dosage, and delivery method.

Some US-based clinics do offer stem cell procedures under specific regulatory exemptions, but these typically use adipose-derived cells — harvested from the patient's own fat tissue. These are the patient's own aged cells, affected by the same health conditions, lifestyle factors, and biological aging that contributed to the stroke in the first place. Dosages are also generally low, further limiting therapeutic potential.

Patients who seek treatment outside the US are often doing so precisely because international clinics operating under rigorous scientific and quality standards can offer something fundamentally different. At Alevy, we have been working with stem cells in our ISO-certified biotechnology laboratory for over 15 years and providing safe, certified treatments for more than a decade. Our protocols use fresh Wharton's jelly mesenchymal stem cells sourced from healthy newborn umbilical cord tissue — biologically young, high potency cells that are ISCT compliant and unaffected by the patient's age or medical history. This is not a workaround. It is a clinically superior approach backed by peer-reviewed research, delivered by board-certified physicians in a certified facility.

The cost of stem cell therapy for stroke varies depending on several factors specific to each patient — including the cell dosage recommended, the delivery method, the complexity of the case, and any complementary therapies indicated as part of the protocol. A single price does not apply across all patients because no two treatment plans are identical.

What we can tell you is that treatment at Alevy includes far more than the stem cell administration itself. Your protocol encompasses a comprehensive medical evaluation, customized treatment plan, laboratory processing, all clinical procedures, complementary therapies, bilingual patient care support, and post-treatment follow-up monitoring.

The most accurate way to understand what treatment would cost for your specific situation is to submit your medical history for review. Our medical  team will prepare a personalized protocol with full details at no cost and with no commitment required. You can request yours by filling out the form and requesting a call from out Patient care Specialists.

Stem cell therapy for stroke is not widely available in the United States or Canada due to FDA regulatory restrictions that limit cell sourcing, expansion, dosage, and protocol design. Patients who are serious about accessing the most advanced regenerative treatment available typically look outside North America where clinics can offer protocols that the US and Canadian markets currently cannot.

Alevy has locations in Medellin and Pereira, Colombia. We have been providing stem cell therapy for neurological conditions for over a decade, operating out of our ISO-certified biotechnology laboratory with ISCT-compliant protocols and board-certified physicians.

Colombia has become one of the leading destinations for medical tourism in Latin America precisely because of the quality of care available at a fraction of the cost patients would expect in North America, without compromising on clinical standards. For stroke survivors specifically, Pereira offers something most places cannot: a clinic with over 10 years of stem cell and exosome experience, fresh Wharton's jelly MSCs processed on site at our lab with 15 years of experience, and intrathecal delivery protocols matched to the chronic recovery phase.

To find out whether treatment at Alevy is appropriate for your specific situation, request a personalized protocol by requesting an appointment at the top of the page.